DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Biosimilar
Biosimilar
The Evolution of Biosimilars in Oncology, with a Focus on Trastuzumab
Biopharmaceutical Notes
Getting to Lower Prescription Drug Prices the Key Drivers of Costs and What Policymakers Can Do to Address Them
The Process Defines the Product: What Really Matters in Biosimilar Design and Production?
Filgrastim (Neupogen®); Filgrastim-Aafi (Nivestym™); Filgrastim- Sndz (Zarxio™); Tbo-Filgrastim (Granix®) (Subcutaneous/Intravenous)
2019 FDA Biopharmaceutical Approvals: a Record Year for Follow-On Products, but Is Innovation Lagging? Bioplan Associates, Inc
Insulin Glargine-Yfgn Injection) for the Treatment of Diabetes”
Biosimilar Cost Savings in the United States Initial Experience and Future Potential
Biological Product Definitions
Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
Concerns About the Use of Biosimilar Granulocyte Colony-Stimulating Factors for the Mobilization of Stem Cells in Normal Donors
The Science Behind Biosimilars
Immunogenicity of Biosimilar Monoclonal Antibodies Vera Brinks, Msc, Phd
Granulocyte-Colony Stimulating Factor Biosimilars
How Risky Is Pfizer's Launch of Its Remicade Biosimilar?
Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Ce
Biosimilar Drugs As More Biosimilar Drugs Come to the Canadian Market, Decision-Makers Need Information to Help Guide Prescribing and Policy Development
Biosimilar Vs. Generic, What's the Difference?
Top View
Biosimilar Drugs
Semglee® (Insulin Glargine-Yfgn) – First New Interchangeable Biosimilar Approval
5.01.551 Granulocyte Colony-Stimulating Factor (G-CSF) Use in Adult
Current and Future Perspectives on the Development of Biosimilar Insulins for Diabetes Management
Meet the Biosimilar Believers
NEUPOGEN (Filgrastim), GRANIX (Tbo-Filgrastim), NIVESTYM (Filgrastim-Aafi), ZARXIO (Filgrastim-Sndz) RATIONALE for INCLUSION IN
Biosimilars in the EU Information Guide for Healthcare Professionals
The Impact of Biosimilar Competition in Europe Contents
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Recent Trends in the Regulation of Biopharmaceuticals: Indonesian Perspectives
Expanding Access to Monoclonal Antibody-Based Products
The Biosimilar Landscape: an Overview of Regulatory Approvals by the EMA and FDA
Follow-On Biologic Drug Competition Federal Trade Commission Report | June 2009 FEDERAL TRADE COMMISSION
List Item Towards Biosimilar Monoclonal Antibodies
Growth Hormone Policy #: 565P
Pharmer's Market: How Biosimilars Are Shaking up the Pharmaceutical Landscape
Emergence of Bevacizumab As Biosimilar with Ophthalmologic Prospects for Patients and Pharma Industry
(Avastin®) and Bevacizumab Biosimilars
Era of Biosimilars in Rheumatology: Reshaping the Healthcare Environment
Biosimilar Insulins: Issues and Considerations Before Clinical Use
What Are Biosimilar Drugs?
Effective Serum Level of Etanercept Biosimilar and Effect of Antidrug Antibodies on Drug Levels and Clinical Efficacy in Chinese Patients with Ankylosing Spondylitis
GP2015 Biosimilar (Etanercept)
How Biosimilar Disparagement Violates Antitrust Law
Biopharmaceuticals and Biosimilars: a Consensus Statement
Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab
Childhood Growth Hormone Treatment in Women with Turner Syndrome
NIVESTYM (Filgrastim-Aafi) Is Biosimilar* to NEUPOGEN (Filgrastim)
Biopharmaceutical and Biosimilar Products in Brazil: from Political to Biotechnological Overview Angelina M
Introduction of Biosimilar Monoclonal Antibodies: the Changing Face of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Treatment
Biosimilar Preferred Products Established For
Biosimilar Medicines Handbook
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
Biosimilars Vs. Generics. Biosimilars Are Becoming More and More Common in the United States
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Biosimilar and Interchangeable Biological Products: Basic Concepts and Practical Resources